Completion of Hepatitis B Vaccination Series by 18 Months in Infants Who Did Not Receive a Birth Dose - Summary - MDSpire

Completion of Hepatitis B Vaccination Series by 18 Months in Infants Who Did Not Receive a Birth Dose

  • By

  • Joshua T. B. Williams

  • Hannah Cruz

  • Amy Stein

  • Kristin Breslin

  • Michaela Brtnikova

  • Bradley Crane

  • Stephanie A. Irving

  • Sungching Glenn

  • Tat’Yana Kenigsberg

  • Bruno Lewin

  • Sara Tartof

  • Maria E. Sundaram

  • Sharon Fuller

  • Teresa Schmidt

  • Sean O’Leary

  • Daniela Canedo

  • Jason M. Glanz

  • Malini DeSilva

  • Candace C. Fuller

  • Ousseny Zerbo

  • Simon J. Hambidge

  • April 24, 2026

  • 0 min

Share

Objective:

To understand longitudinal trends in infant hepatitis B vaccine series completion through age 18 months, stratified by birth dose receipt, and to assess the implications for public health policy.

Key Findings:
  • 87.1% of children were fully vaccinated by 18 months, indicating high overall coverage.
  • 81.2% received a hepatitis B birth dose, which is crucial for series completion.
  • 3-dose coverage among those who received a birth dose exceeded 97%, demonstrating effectiveness.
  • 3-dose coverage for those without a birth dose declined from 73.2% in 2014 to 55.3% in 2023, highlighting significant disparities.
  • Disparities in series completion were noted by race, ethnicity, and language, necessitating targeted interventions.
Interpretation:

High vaccination coverage exists among those receiving a birth dose, while those without show significant declines and disparities, underscoring the need for targeted public health strategies to address these gaps.

Limitations:
  • Study conducted in primarily privately insured health care systems, which may not represent all populations.
  • Local differences in coding practices for demographic data could introduce bias.
  • Missing data on race and language in some sites limits comprehensive analysis.
Conclusion:

Findings underscore the need for monitoring birth dose refusal and improving communication strategies regarding hepatitis B vaccines, particularly targeting at-risk populations.

Original Source(s)

Related Content